Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated)
Accession Number
DB14384
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Description

Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) is a vaccine.

Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
Influenza a virus a/victoria/210/2009 x-187 (h3n2) antigen (formaldehyde inactivated)unknown3Q2OMA2GNKNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Fluarix 2010/2011Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza a virus a/california/7/2009 x-181 (h1n1) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2010-08-092010-08-02Us
Categories
UNII
3Q80689L6F
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with 2-Methoxyethanol.
25-desacetylrifapentineThe therapeutic efficacy of Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with 25-desacetylrifapentine.
6-Deoxyerythronolide BThe therapeutic efficacy of Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Abetimus.
Acetic acidThe therapeutic efficacy of Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Acetic acid.
Acetyl sulfisoxazoleThe therapeutic efficacy of Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) is combined with Acetylsalicylic acid.
ActeosideThe therapeutic efficacy of Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Acteoside.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on July 05, 2018 12:02 / Updated on May 01, 2019 11:59